Twenty-five cell lines derived from nine different human cancers were tested for the cytotoxic
activity of suramin. Two different initial cellular concentrations were used: C1 (800–2000 …

Suramin cytotoxicity was studied in a panel of human lung cancer cell lines by the MTT
assay. The concentrations of suramin which induced 50% growth inhibition (ic50) ranged …

Suramin has been shown to have antiproliferative activity, either by blocking the binding of
growth factors to their receptors or by inhibiting critical cellular enzymes. In 6 different cell …

Suramin has shown antitumour activity in vitro and in vivo. At plasma levels higher than 200
μM there is, however, excessive toxicity. We have, therefore, attempted to improve the …

Suramin has shown promising antitumour activity against several tumour types, both in vitro
and in vivo, but the clinical utility of this compound is hampered by its unfavourable toxicity …

Suramin is an antitrypanosomal compound with confirmed efficacy against several human
malignancies. It is generally assumed that its mechanism of action includes the interaction …

Suramin, a non‐specific growth factor antagonist, is currently under investigation for
treatment of cancer patients. We studied its action on 6 different human breast‐cancer cell …

Background: Suramin is a polysulfonated urea recently tested in clinical trials as an
anticancer agent. Purpose: To define tumor types for further clinical testing of suramin, we …

Conclusion and perspectives At present the primary mechanism (s) of suramin action is not
known. It is possible that several of the factors mentioned in this review are of importance for …

Suramin is a polysulfonated compound originally developed nearly 75 years ago for use as
a trypanocidal agent. Recent studies indicate that suramin can also disrupt mammalian cell …